학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 2,449건 | 목록 1~20
Conference
2025 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR) CVPR Computer Vision and Pattern Recognition (CVPR), 2025 IEEE/CVF Conference on. :11227-11238 Jun, 2025
Academic Journal
Tiew-Hwa Katherine TengCarolyn S.P. LamA. Mark RichardsInder AnandChung-Lieh HungLieng Hsi LingHoung Bang LiewCalambur NarasimhanTachapong NgarmukosSang Weon ParkEugenio ReyesBambang B. SiswantoWataru ShimizuShu ZhangXiaohan FanKeping ChenLiqun WuYucai XieQi JinTianyou LingXinli LiFang ZhouYanli ZhouDongjie XuHaifeng ZhangYangang SuXueying ChenShengmei QinJingfeng WangXue GongZhaodi WuCheuk Man YuB.K.S. SastryArun GopiK. RaghuC. SrideviDaljeet KaurAjay NaikKeyur ParikhAnish ChandaranaUrmil ShahMilan ChagHemang BaxiSatya GuptaJyoti BhatiaVaishali KhakhkharVineet SankhlaTejas PatelVipul KapoorGurpreet Singh WanderRohit TandonVijay ChopraManoj KumarHatinder Jeet Singh SethiRashmi VermaSanjay MittalJitendra SawhneyManish Kr. SharmaMohanan Padinhare PurayilBambang Budi SiswantoPintoko TedjokusumoErwan Martantonull ErwinantoMuhammad MunawarJimmy Agung PambudiAntonia LukitoIngrid PardedeAlvin ThengkerVito DamaySiska Suridanda DannyRarsari SurarsoTakashi NodaIkutaro NakajimaMitsuru WadaKohei IshibashiTakashi KuritaRyoubun YasuokaKuniya AsaiKohji MuraiYoshiaki KubotaYuki IzumiTakanori IkedaShinji HisatakeTakayuki KabukiShunsuke KiuchiNobuhisa HagiwaraAtsushi SuzukiTsuyoshi SuzukiSang-Weon ParkSuk Keun HongSookJin LeeLim Dal SooDong-Hyeok KimJaemin ShimSeong-Mi ParkSeung-Young RohYoung Hoon KimMina KimJong-Il ChoiJin Oh NaSeung Woon RhaHong Seog SeoDong Joo OhChang Gyu ParkEung Ju KimSunki LeeBoyoung JoungJae-Sun UhmMoon Hyoung LeeIn-Jeong ChoHui-Nam ParkHyung-Wook ParkJeong-Gwan ChoNamsik YoonKiHong LeeKye Hun KimSeong Hwan KimSahrin SaharudinBoon Cong BehYu Wei LeeChia How YenMohd Khairi OthmanAmie-Anne AugustineMohd Hariz Mohd AsnawiRoberto Angelo MojolouYou Zhuan TanAida Nurbaini ArbainChii Koh WongRazali OmarAzmee Mohd GhaziSurinder Kaur KhelaeDavid S.P. ChewLok Bin YapAzlan HussinZulkeflee MuhammadMohd. Ghazi AzmeeImran Zainal AbidinAhmad Syadi Bin Mahmood ZhudiNor Ashikin Md SariGaniga Srinivasaiah SridharAhmad Syadi Mahmood ZuhdiMuhammad Dzafir IsmailTiong Kiam OngYee Ling ChamNing Zan KhiewAsri Bin SaidAlan Yean Yip FongNor Hanim Mohd AminKeong Chua SengSian Kong TanKuan Leong YewJones SantosAllan LimRaul LapitanRyan AndalEleanor LopezKheng Leng David SimBoon Yew TanChoon Pin LimLouis L.Y. TeoLaura L.H. ChanPing ChaiChing Chiew Raymond WongKian Keong PohPoh Shuan Daniel YeoEvelyn M. LeeSeet Yong LohMin Er ChingDeanna Z.L. KhooMin Sen YewWenjie HuangKui Toh Gerard LeongJia Hao Jason SeeYaozong Benji LimSvenszeat TanColin YeoSiang Chew ChaiFazlur Rehman JaufeerallyHaresh TulsidasThan AungHean Yee OngLee Fong LingDinna Kar Nee SoonHung-I YehJen-Yuan KuoChih-Hsuan YenJuey-Jen HwangKuo-Liong ChienTa-Chen SuLian-Yu LinJyh-Ming JuangYen-Hung LinFu-Tien ChiangJiunn-Lee LinYi-Lwun HoChii-Ming LeePo-Chih LinChi-Sheng HungSheng-Nan ChangJou-Wei LinChih-Neng HsuWen-Chung YuTze-Fan ChaoShih-Hsien SungKang-Ling WangHsin-Bang LeuYenn-Jiang LinShih-Lin ChangPo-Hsun HuangLi-Wei LoCheng-Hsueh WuHsin-Yueh LiangShih-Sheng ChangLien-Cheng HsiaoYu-Chen WangChiung-Ray LuHung-Pin WuYen-Nien LinKe-Wei ChenPing-Han LoChung-Ho HsuLi-Chuan HsiehMann ChandavimolTeerapat YingchoncharoenPrasart LaothavornWaraporn TiyanonWanwarang WongcharoenArintaya Phrommintikul
JACC Asia
Conference
2024 IEEE Spoken Language Technology Workshop (SLT) Spoken Language Technology Workshop (SLT), 2024 IEEE. :570-577 Dec, 2024
Academic Journal
2025 62nd ACM/IEEE Design Automation Conference (DAC). :1-7
Academic Journal
International Journal of Economics, Finance and Management Sciences. 13:210-221
Conference
2023 IEEE Automatic Speech Recognition and Understanding Workshop (ASRU) Automatic Speech Recognition and Understanding Workshop (ASRU), 2023 IEEE. :1-8 Dec, 2023
Report
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).
Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.
Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001 Aug;7(8):2182-94.
Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75. doi: 10.1016/j.tiv.2005.06.045. Epub 2005 Nov 3.
Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991 Aug 15;51(16):4187-91.
Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002 Mar;8(3):641-61.
Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001 Mar 1;19(5):1501-18. doi: 10.1200/JCO.2001.19.5.1501.
Lee DH, Kim HT, Han JY, Lee SY, Yoon SJ, Kim HY, Lee JS. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naive patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer Chemother Pharmacol. 2008 Jan;61(1):83-8. doi: 10.1007/s00280-007-0450-7. Epub 2007 Apr 28.
Chen SC, Chang PM, Yang MH. Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study. Oncologist. 2016 May;21(5):537-8. doi: 10.1634/theoncologist.2015-0515. Epub 2016 Apr 18.
Tsai CS, Park JW, Chen LT. Nanovector-based therapies in advanced pancreatic cancer. J Gastrointest Oncol. 2011 Sep;2(3):185-94. doi: 10.3978/j.issn.2078-6891.2011.034.
Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY, Chen LT. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86. doi: 10.1007/s00280-014-2671-x. Epub 2015 Jan 11.
Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang YW, Yeh CG, Chen LT. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer. 2016 Nov 21;16(1):907. doi: 10.1186/s12885-016-2933-6.
Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. doi: 10.1093/annonc/mdt002. Epub 2013 Feb 13.
Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20;109(4):920-5. doi: 10.1038/bjc.2013.408. Epub 2013 Jul 23.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29.
Report
A Phase I/II Study of Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinoma
Report
A Study of Nivolumab Combination Gemcitabine and S1 as the First-Line Treatment in Patients With Advanced Biliary Tract Cancer
Chiang NJ, Tang CY, Bai LY, Chang PC, Chen WM, Kang ST, Chen SC, Chen MH, Hsieh JC. Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study. NPJ Precis Oncol. 2025 Aug 30;9(1):307. doi: 10.1038/s41698-025-01099-x.
Conference
2024 International Conference on Artificial Intelligence in Information and Communication (ICAIIC) Artificial Intelligence in Information and Communication (ICAIIC), 2024 International Conference on. :1-6 Feb, 2024
검색 결과 제한하기
제한된 항목
[검색어] Chang, Chung-Ho
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어